Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, AVANOS MEDICAL, INC. reported revenue of $701M, up 1.9% year over year. Operating margin was -8.8% and net margin -10.4%, on a free-cash-flow margin of 6.1% with capital expenditure at 4.5% of revenue. Every figure is computed directly from AVNS's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $701M | -8.8% | -10.4% |
| FY2024 | $688M | -57.6% | -57.0% |
| FY2023 | $673M | 0.6% | -9.2% |
| FY2022 | $684M | 5.2% | 7.4% |
| FY2021 | $587M | -6.6% | 1.1% |
How does AVNS compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: A · ACHR · AEHR · AERG · AEVA · AIRI
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.